Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEORY: Obinutuzumab for Desensitization in ESRD
NCT02586051Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of obinutuzumab in sensitization in kidney transplantation (PRA) (2 cohorts), sponsored by Roche. Primary endpoint: Percentage of Participants with Adverse Events. Started Nov 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
sensitization in kidney transplantation (PRA)
Beyond the preview
Go deeper on NCT02586051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586051.